Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070941 · ClinicalTrials.gov registry record · Phase 2
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
A Phase 2 study of Depression and Parkinson's Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00070941: Completed Phase 2 study of Depression and Parkinson's Disease, sponsored by NYU Langone Health.
NCT00070941 is a Phase 2 study of Depression and Parkinson's Disease that has completed, run by NYU Langone Health. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070941, a Phase 2 study of Depression and Parkinson's Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Primary Outcome
very severe, \>23/29; severe, 19-22/29; moderate, 14-18/29; mild, 8-13/29; and no depression, 0-7/29 (Hamilton M., J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.)
Conditions Studied
Interventions
- DRUG placebo
- DRUG SAM-e
- DRUG oral escitalopram
Study Locations (1)
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2003-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
What the finished NCT00070941 record still lists
NCT00070941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00070941 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00070941 about?
NCT00070941 is a clinical study titled "SAM-e for the Treatment of Depression in Patients With Parkinson's Disease". This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
What is the current status of trial NCT00070941?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2003-07. Estimated completion is 2010-10.
What conditions does trial NCT00070941 study?
This clinical trial studies the following conditions: Depression, Parkinson's Disease.
What interventions are being tested in trial NCT00070941?
The interventions under investigation include: placebo (DRUG), SAM-e (DRUG), oral escitalopram (DRUG).
Who is sponsoring clinical trial NCT00070941?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070941 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00070941's enrollment target sits among peer trials
29 576th of 679 higher than 99 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
- NCT03531450 · 29 participants · NA
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia